



## **FOR IMMEDIATE RELEASE**

### **Pique Therapeutics Reaches 50 Patients in Phase 2 Clinical Trial of PT 107 in Non-Small Cell Lung Cancer**

**Durham, North Carolina** – March 5, 2013 -- Pique Therapeutics, Inc. announced today that it has reached the halfway point in the Phase 2 clinical trial of its lead program, PT 107, for the treatment of non-small cell lung cancer. To date, 50 patients have been enrolled in the trial.

As detailed in the Phase 2 protocol, the Company will conduct an interim analysis of the trial following 6 months from the fiftieth patient's entry into the study. As such, the Company expects to have interim results in September 2013.

The Phase 2 program is a randomized double-blind, placebo-controlled clinical trial, enrolling 100 patients with Stage IIIB/IV non-small cell lung cancer who have failed previous therapy. The Phase 2 trial seeks to confirm the safety of PT 107, and further evaluate the efficacy of the drug.

#### **About Pique Therapeutics**

Pique Therapeutics is a biopharmaceutical company seeking to become the leader in the development and commercialization of new therapeutic vaccines, focused initially on the treatment of cancer. The Company was founded on the research of Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami.

#### **About PT 107**

Pique's lead product, PT 107, is a first-in-class therapeutic vaccine for the treatment of non-small cell lung cancer and has completed Phase 1 clinical trials, where it was well tolerated, and exhibited a very good safety profile in cancer patients. PT 107 showed a dramatic improvement in median overall survival (11 months) for patients with second-line, late-stage non-small cell lung cancer, more than doubling the expected 4 to 6 months survival in these patients. Remarkably, over 30% of PT 107-treated patients survived 4 years or longer, while currently-approved treatments extend overall survival in this group of patients by approximately 2-3 months.

#### **Contact:**

Christopher S. Meldrum  
President  
Pique Therapeutics, Inc.  
(919) 806-4395